Display options
Cite
Kutz C. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Ther Adv Chronic Dis. 2016;7(4):190-7doi: 10.1177/2040622316644481.
Kutz, C. (2016). H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Therapeutic advances in chronic disease, 7(4), 190-7. https://doi.org/10.1177/2040622316644481
Kutz, Christen. "H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes." Therapeutic advances in chronic disease vol. 7,4 (2016): 190-7. doi: https://doi.org/10.1177/2040622316644481
Kutz C. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes. Ther Adv Chronic Dis. 2016 Jul;7(4):190-7. doi: 10.1177/2040622316644481. Epub 2016 Jun 10. PMID: 27433309; PMCID: PMC4935834.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Chronic Dis. 2016 Jul;7(4):190-7. doi: 10.1177/2040622316644481. Epub 2016 Jun 10.

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes.

Therapeutic advances in chronic disease

Christen Kutz

Affiliations

  1. Colorado Springs Neurological Associates, 2312 North Nevada Avenue, Colorado Springs, CO 80907, USA.

PMID: 27433309 PMCID: PMC4935834 DOI: 10.1177/2040622316644481

Abstract

BACKGROUND: Treatment of multiple sclerosis (MS) relapses can be complex in patients with concomitant diabetes. Corticosteroids and adrenocorticotropic hormones are known to cause alterations in glucose tolerance. Many patients have poor tolerability to therapy, necessitating alternative treatment options. Adrenocorticotropic hormone (H.P. Acthar Gel, repository corticotropin injection, Mallinckrodt ARD Inc., Hazelwood, MO, USA) is currently indicated for the treatment of MS relapses.

OBJECTIVES: The objective of this study was to review patients' experiences of Acthar Gel for the treatment of MS exacerbations in patients with MS and diabetes.

METHODS: A retrospective review of 13 patients' experiences with treatment. Qualified healthcare providers completed a questionnaire following Acthar Gel treatment for MS relapse.

RESULTS: Previous corticosteroid treatment with either intravenous methylprednisolone or prednisone was reported by 84.6% of patients; eight patients had complications following administration of prior steroid treatment, seven of whom experienced elevated blood glucose levels. Acthar Gel was administered daily for a mean of 5.3 days, with 61.5% of patients reporting relapse resolution. Two patients experienced elevated blood glucose.

CONCLUSION: The majority of patients experienced a timely resolution of their MS relapse with few hyperglycemic adverse events. Although more studies are necessary, these data suggest that Acthar Gel may be a well-tolerated and effective treatment option for patients with diabetes experiencing an MS relapse.

Keywords: Acthar Gel; blood glucose; diabetes mellitus; hyperglycemia; multiple sclerosis; steroids

References

  1. Clin Neurol Neurosurg. 2014 Apr;119:6-16 - PubMed
  2. Lancet. 2008 Oct 25;372(9648):1502-17 - PubMed
  3. Diabetes Res Clin Pract. 2013 Mar;99(3):277-80 - PubMed
  4. Eur J Neurol. 2008 Mar;15(3):284-8 - PubMed
  5. Brain. 1989 Feb;112 ( Pt 1):133-46 - PubMed
  6. Brain. 2003 Apr;126(Pt 4):770-82 - PubMed
  7. Exp Neurol. 2005 Aug;194(2):376-83 - PubMed
  8. J Neurosci. 2006 May 24;26(21):5709-19 - PubMed
  9. J Neurochem. 1999 Aug;73(2):693-9 - PubMed
  10. Acta Neurol Scand Suppl. 2009;(189):73-80 - PubMed
  11. Neurology. 2015 Jul 21;85(3):240-7 - PubMed
  12. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511-6 - PubMed
  13. J Neurochem. 2003 Feb;84(4):705-16 - PubMed
  14. J Neurosci. 2010 Oct 13;30(41):13690-8 - PubMed
  15. Am J Nephrol. 2012;36(1):58-67 - PubMed
  16. Nephrol Dial Transplant. 2014 Aug;29(8):1570-7 - PubMed
  17. Neurotherapeutics. 2013 Jan;10(1):97-105 - PubMed
  18. Nutrition. 2014 Mar;30(3):268-73 - PubMed

Publication Types